Drugmaker GlaxoSmithKline was fined $492 million on Friday for bribing doctors in China, the biggest such penalty ever imposed by a Chinese court.
Pfizer's second-quarter earnings plunged 79% from last year, when the world's second-largest drugmaker booked a $10 billion-plus gain from a business spinoff.
A big one-time gain and a tax benefit helped drugmaker Merck & Co. more than double its second-quarter profit, improve its profit forecast and top analysts' expectations.
A costly drug given mostly to premature babies is at the center of a clash between the manufacturer and the nation's leading pediatrician's group, which recommends scaling back use of the medicine.
The rumblings that corporate tax reform will close favorable loopholes for pharmaceutical and biotechnology companies are getting louder, fueling a rush of high-dollar cross-border deals.
New drugs are making a dent against some hard-to-treat cancers, but some results raise fresh questions about whether the benefit is worth the cost.
Pfizer said Monday that it does not intend to make a takeover offer for British drugmaker AstraZeneca, pulling the plug for now on what would have been the largest deal in the industry's history.
With a May 26 deadline looming, British drug giant AstraZeneca is holding firm in its refusal to accept a $119 billion offer from Pfizer to create the world's largest pharmaceutical company.
With a May 26 deadline looming, British drug giant AstraZeneca is holding firm in its refusal to accept a $119 billion offer from rival Pfizer to create the world's largest pharmaceutical company. The record-setting offer is just one of a slew of mega-deals this year in the pharmaceutical and...
British drug maker AstraZeneca rejected Monday what its New York-based rival Pfizer called over the weekend its "final" takeover offer.
Several hundred women are suing Pfizer in federal court, alleging the company knew that women taking Lipitor faced an increased risk of developing Type 2 diabetes and that Pfizer's warning label did not clearly describe that risk.
Pfizer, one of the nation's largest pharmaceutical companies, stands locked in a takeover battle with British drugmaker AstraZeneca. Its earnings Monday pointed to why it needs a conquest to pump up its new drug development pipeline through a major acquisition.